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ABSTRACT
Many genotoxic chemotherapies have debilitating side effects and induce cellular senescence in normal
tissues. Senescent cells acquire a pro-inﬂammatory phenotype which contributes to local and systemic
inﬂammation. Eliminating senescent cells reduce several short- and long-term effects of the drugs,




Genotoxic and cytotoxic drugs are widely used as anticancer
treatments and act by non-speciﬁcally targeting proliferative
cells through different mechanisms. The toxicity of chemo-
therapies for many types of dividing cells leads to a number of
adverse reactions, which include immunosuppression, pain,
fatigue, anemia, nausea, gastrointestinal distress, and hair loss.1
Moreover, clinical studies of cancer survivors treated during
childhood suggest that chemotherapy causes a range of diseases
normally associated with aging.2
Many chemotherapeutic drugs induce changes of cellular
states in the tumor microenvironment, including cellular senes-
cence.3 Cellular senescence is a complex stress response
whereby cells irreversibly lose the capacity to proliferate due to
induction of the CDKN2A gene (from now on p16INK4a), a
potent Cyclin-Dependent Kinases (CDK) 4/6 inhibitor. More-
over, senescent cells are characterized by numerous changes in
gene expression, including the activation of the Senescence-
Associated Secretory Phenotype (SASP).4 We and others have
suggested that the secretory phenotype associated with senes-
cent cells (SASP) can serve several biological functions, either
beneﬁcial or deleterious.5 Among the deleterious effects, the
excessive persistence of senescent cells can disrupt tissue
homeostasis and drive the onset or progression of several dis-
eases, particular age-related pathologies.6 Accordingly, therapy-
induced senescence (TIS) is thought to have both positive and
negative roles in the body: on one side, senescent cells and the
SASP can stimulate immunosurveillance to eliminate tumor
cells; on the other side, the prolonged presence of senescent
cells can potentially be a source of chronic inﬂammation and
drug resistance.7
Using a mouse model (p16-3MR) in which p16INK4a-positive
senescent cells can be detected in living animals and eliminated
upon treatment with an otherwise benign drug,8 we have
recently shown that TIS cells contributed to a number of
chemotherapy-associated side effects.9 First, senescent cells
promoted the increased expression of pro-inﬂammatory and
SASP-related factors in tissue and sera observed in chemother-
apy-treated mice. Second, elimination of senescent cells con-
tributed to the functional re-activation of Haematopoietic
Progenitor Cells (HPCs), thus accelerating the recovery from
bone marrow suppression. Third, endothelial cells were
induced to senescence in the heart and, together with higher
levels of circulating pro-inﬂammatory factors, induced the
development of cardiac dysfunction. Fourth, senescent non-
tumor cells were an important component for cancer relapse
after chemotherapy, and their elimination also dramatically
reduced the number of metastasis in a model of breast cancer.
Fifth, clearing senescent cells improved the spontaneous physi-
cal activity and overall strength in the presence or absence of
cancer. In order to validate these effects in a human cohort, we
measured p16INK4a expression in peripheral T-cells of human
patients with breast cancer. Strikingly, we observed a strong
direct correlation between high level of p16INK4a-positive senes-
cent cells and the severity of chemotherapy-induced fatigue.
These data are in accordance with recent ﬁndings showing that
aging is the major risk factor for long-term (>2 or >5 years)
fatigue after chemotherapy treatment.10
These results show that a variety of DNA-damaging agents
potently and rapidly increase the in vivo burden of senescent
cells in humans and mice, and the accumulation of such cells
causes a number of adverse reactions. Considering that some of
the chemotherapy-induced and senescence-dependent side
effects, such as bone marrow suppression and cardiac dysfunc-
tion, are major limiting factors for the drug dosage in cancer
patients, it is conceivable to consider the development of thera-
pies that can selectively target senescent cells (senolytics) and/
or the SASP. In our work, we showed that the administration
of a senolytic agent, ABT-263, efﬁciently eliminated senescent
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cells, improved physical activity, and reduced cancer relapse in
mice treated with chemotherapy. Thus, pharmacological
removal of senescent cells might be an innovative combinato-
rial approach to limit some toxicity associated to chemothera-
pies, with consequent improvements in the health span and
possibly life span of cancer patients.
However, these interventions will need to carefully consider
any beneﬁcial effects of TIS, including promotion of tissue
repair and of tumor immunosurveillance.
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